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Depression is one of the most common forms of mental illness.  Despite decades of 
research, the mechanisms underlying this disorder remain unknown.  To help 
elucidate the pathophysiology of depression, researchers are developing animal 
models of psychiatric disorders, including depression, and assessing for mood-
related phenotypes.  There are a limited number of behavioral assays available to 
assess depression-like behaviors in rodents but by far the most common is the 
forced swim test (FST).  Although the FST is considered the gold standard for 
studying depression-like behaviors there are strong reasons to question the 
interpretation that immobility represents ‘despair’ and escape-directed behaviors 
such as climbing represent the absence of a depression-like phenotype.  It has 
recently been proposed that immobility in the FST is an adaptive learned response 
and reflects a switch from active to passive coping strategies (de Kloet and 
Molendijk, 2016).  While we agree with de Kloet and Molendijk (2016) that 
immobility is adaptive we disagree on the interpretation of active versus passive 
coping strategies.  Instead we believe that escape-directed behaviors are driven by 
anxiety.  We argue this perspective on the basis of comorbidity, gene targeting, and 
pharmacological studies.  
Depression rarely strikes alone.  In clinical populations, depression is highly 
comorbid with anxiety disorders, with estimates as high as 80% (Lamers et al, 
2011).  Despite the high degree of comorbidity between depression and anxiety in 
clinical populations there are only a few studies examining individual differences in 
comorbidity between depression- and anxiety-like behaviors in rodents.  One study 
found no relationship between performance on the FST and the elevated plus maze 
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(EPM) (Ho et al, 2002), whereas another study reported an inverse relationship 
between performance on the FST and the EPM.  In other words, animals that were 
high on measures of depression-like behaviors were low on measures of anxiety-
like behaviors (Estanislau et al, 2011).  More recently, we conducted a study looking 
at individual differences in depression- and anxiety-like behaviors where our results 
are more consistent with Estanislau and colleagues (2011). The inverse relationship 
between depression- and anxiety-like behaviors is surprising as it is diametrically 
opposed to human clinical populations.  There are two possible explanations for the 
discrepancies between human and animal research: either, the underlying 
mechanisms driving depression and anxiety are distinct in humans and rodents, or 
we are misinterpreting animal behavior.  We believe the underlying mechanisms are 
conserved and therefore it is more likely due to interpretation error. 
While comorbidity is the norm within clinical populations, much less is 
known about comorbidity in standard lab rodents.  Different methodologies can be 
employed in the search for parallels between human comorbidity and animal 
models including gene knockouts (KO), selective breeding, and RNA interference.  
Although there are numerous animal models at one’s disposal, we address two KO 
models: the serotonin transporter (5-HTT) KO and the serotonin 1A receptor (5-
HT1A) KO.  These KO lines were chosen because the 5-HT system is implicated in 
both depression and anxiety disorders in clinical populations and that the most 
commonly used drugs to treat these disorders target the 5-HT system.  
The precise mechanisms underlying the therapeutic effects of SSRIs have yet 
to be elucidated, however, it is known that SSRIs increase the amount of 5-HT 
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available at the synaptic cleft through blocking the re-uptake of 5-HT at 5-HTT sites.  
Holmes and colleagues (2003) have done extensive work characterizing the 
phenotype of 5-HTT KO mice and demonstrated that they exhibit increased anxiety-
like behaviors in the EPM, open field, and light-dark box, spend more time immobile 
in the FST, are more passive and less aggressive in the resident-intruder paradigm, 
but are also less active overall as measured by baseline activity in their homecage 
(see Holmes et al, 2003).  Considering that 5-HTT KO exhibit increased anxiety-like 
behaviors across a host of behavioral tests and spend more time immobile in the 
FST one could argue that knocking out 5-HTT generates an animal model of 
comorbid depression- and anxiety-like behavior.  The fact that this KO model is 
generally less active is important to note because anxiety-like phenotypes are often 
based on activity levels, such as reduced exploratory activity in the open field and 
exploration of the EPM.  As such, the general blunting of activity in 5-HTT KOs raises 
the question: can an overall reduction in activity account for the increased 
immobility observed in the FST as well as the anxiety-like phenotype?  Given this 
caveat, researchers using KO models should pay close attention to overall activity 
levels to rule out this possibility.  
In their work with the 5-HTT KOs, Holmes et al., (2003) found that the 
anxiogenic phenotype is mediated through 5-HT1A receptors.  As with the 5-HTT 
gene, the 5-HT1A receptor has been implicated in mood and anxiety in humans.  5-
HT1A receptor KO mice exhibit increased anxiety-like behaviors (Klemenhagen et al, 
2006) as well as increased escape-directed behaviors in the FST (Freeman-Daniels 
et al, 2011), making 5-HT1A KOs similar to 5-HTT KOs in respect to anxiety-like 
Neuropsychopharmacology, In Press 5 
behaviors but opposite in respect depression-like behaviors in the FST.  Both the 5-
HTT and the 5-HT1A receptor are implicated in depression and anxiety in humans, 
yet KO mouse lines exhibit different behavioral phenotypes.  To explain these 
differences, we maintain that the ‘depression-like’ phenotype associated with 5-HTT 
KO is the result of an overall blunting of activity.  In respect to the 5-HT1A KO, we 
argue that the persistance of escape-directed behavior in the FST does not represent 
an antidepressant-like response, but is instead caused by the anxiogenic effect of 
knocking out 5-HT1A receptors.  
In addition to exhibiting an anxiety-like phenotype, 5-HT1A KOs also exhibit 
deficits in hippocampal-dependent learning tasks including contextual fear 
conditioning (Klemenhagen et al, 2006). There are a number of convincing lines of 
evidence which support the position that immobility is a learned response 
(reviewed in de Kloet et al, 2016).  In brief, if memory consolidation following the 
habituation phase is blocked with the protein synthesis inhibitor anisomycin, 
animals do not become immobile on the test day 24h later (De Pablo et al, 1989).  
Memory consolidation in the FST appears to be mediated by glucocorticoid signaling 
because adrenalectomy has the same effect on immobility as anisomycin.  Moreover, 
adrenalectomized rats that receive an injection of corticosterone 15-min after the 
habituation trial become immobile on test day (Veldhuis et al, 1985).   
 The claim that the FST measures depression-like behaviors is based on 
evidence from preclinical trials that antidepressant compounds reduce immobility.  
It is consistently shown that an acute injection of a putative antidepressant reduces 
immobility in the FST (see de Kloet and Molendijk, 2016; Van der Meersch-Mougeot 
Neuropsychopharmacology, In Press 6 
et al., 1993).  The fact that acute exposure to an antidepressant can produce an 
antidepressant-like response in rodents has been criticized because antidepressants 
require weeks of chronic use in clinical populations.  Moreover, many patients do 
not respond to the first antidepressant prescribed and many patients are deemed 
treatment-resistant because they do not respond to two or more courses of 
antidepressant treatment.  The issues of delayed onset and questionable efficacy are 
acknowledged in some animal behavior studies, however, the fact that 
antidepressants are associated with the induction or exacerbation of anxiety, 
particularly during the acute stage of treatment, has not been acknowledged.   
 The fact that antidepressants induce or exacerbate anxiety in clinical 
populations suggests that antidepressants would also have anxiogenic properties in 
rodents.  This is particularly important given that protocols designed to assess 
antidepressants in rodents focus on acute exposure to the drug.  Consistent with our 
anxiogenic hypothesis, Silva and colleagues (1999) demonstrated that an acute 
injection of fluoxetine induces anxiety-like behaviors in rodents.  Interestingly, 
chronic exposure to fluoxetine had sustained anxiogenic properties (Silva et al, 
1999).  The lack of anxiolytic properties associated with fluoxetine is surprising 
given that SSRIs are the first line treatment for anxiety disorders.  
 There is evidence from both clinical reports and animal studies 
demonstrating that antidepressants induce anxiety.  Therefore, we must consider 
whether the anxiogenic effects of antidepressants are being misinterpreted as 
antidepressant properties.  If reduced immobility and increased escape-directed 
behaviors are driven by anxiety, it follows that anxiogenic compounds would have 
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an anti-immobility effect in the FST.  Nishimura and colleagues (1989) administered 
either beta-carboline-3-carboxylic acid ethyl ester (β-CCE; an inverse agonist at the 
benzodiazepine receptor site) or diazepam (an anxiolytic) to rats and tested their 
performance on the FST.  They reported increased climbing and escape-directed 
behaviors in animals treated with β-CCE, whereas rats treated with diazepam spent 
significantly more time immobile (Nishimura et al, 1989).  Likewise, the alpha-2-
adrenergic receptor antagonist yohimbine, which exerts its anxiogenic properties 
through antagonism of alpha-2-receptors, has been shown to potentiate the anti-
immobility effects of fluoxetine (Dhir and Kulkarni, 2007).  Furthermore, 
benzodiazepines have also been shown to reverse the anti-immobility effects of 
antidepressants (Van der Meersch-Mougeot et al, 1993).  Interestingly the reversal 
of anti-immobility is specific to antidepressants because benzodiazepines do not 
affect caffeine-induced activity in the FST.  As such, we believe that the anxiolytic is 
attenuating the anxiogenic effect of acute exposure to antidepressants.  Within the 
clinical sphere, some physicians and psychiatrists prescribe an anxiolytic for the 
first weeks when commencing antidepressant treatment in order to manage the 
anxiety associated with the treatment and maintain adherence.  One possible side 
effect of anxiolytics is sedation, thus one could argue that the decreased activity in 
the diazepam condition is driven by the sedative effect of the drug.  Although 
possible, this is unlikely given that anxiolytics promote exploratory activity in the 
EPM.  Therefore, any sedative effects associated with the anxiolytic likely do not 
account for the increase in immobility in the FST.  In summary, there is converging 
evidence from pharmacological studies demonstrating that antidepressants can 
Neuropsychopharmacology, In Press 8 
induce anxiety in both human and animal models.  We argue that the 
antidepressant-induced anxiety is the driving force behind the increased escape-




The FST is a widely used behavioral assay for depression-like behavior yet 
what immobility and escape-directed behaviors mean exactly remains unclear. 
Given the ubiquitous use of the FST to assess mood in gene KOs and other animal 
models of mood, it is necessary to have a clear understanding of what the test 
represents and what the behaviors actually mean.  Drawing upon comorbidity, gene 
KOs and pharmacological studies from both animal models and clinical samples we 
propose an alternative interpretation of the FST.  To further our understanding of 
the FST, future studies can continue to examine comorbidity between depression- 
and anxiety-like behaviors in healthy rodents.  The study of individual differences as 
more of a top-down approach to understanding psychopathology will compliment 
what is learned from bottom-up approaches including gene KOs.  While genetic 
models of mood and anxiety disorders provide insight into molecular pathways of a 
particular state, one must pay attention to confounding effects that can make 
inferring mood states more difficult.  It is also important to focus on sex differences 
in mood-related behaviors.  There are sex differences in the prevalence of 
depression and anxiety disorders in humans, which means future animal studies 
should include both male and female subjects.  Finally, we believe that the 
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understanding and interpretation of animal behavior would be improved by looking 
to clinical research.  Currently there is a resurgence of interest in the therapeutic 
benefits of compounds such as lysergic acid diethylamide and psilocybin.  These 
compounds were not developed for antidepressant or anxiolytic purposes but have 
therapeutic benefits, most likely mediated through their high affinity for 5-HT 
receptors.  It will be interesting to see how these drugs affect performance on the 
FST and other measures of anxiety-like behavior.  When designing experiments with 
these drugs it will be important to look to human clinical trials for the time course. 
For example, it will be important to administer the drug at least 2-3 days prior to 
behavior testing.  In moving forward, it is important that the methodology used in 
animal studies mirrors human clinical trials as closely as possible.  Utilizing similar 
methodologies, in respect to dosages and time course in particular will promote a 
better understand of the relationship between performance on the FST and anxiety-
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